Fecal Microbiota Transplantation & Cancer
Fecal microbiota transplantation in cancer management: Current status and perspectives.
Fecal Microbiota Transplantation: A Potential Tool for Treatment of Human Female Reproductive Tract Diseases.
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.
Fecal microbiota transplantation in disease therapy.
Protective Role of Fecal Microbiota Transplantation on Colitis and Colitis-Associated Colon Cancer in Mice Is Associated With Treg Cells.
The Microbiota and Cancer Cachexia.
Microbiota and gastrointestinal cancer.
Microbiota transplantation: Targeting cancer treatment.
Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer.
The role of microbiota in the development of colorectal cancer.
Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Fecal microbiota transplantation as a new therapy: from Clostridioides difficile infection to inflammatory bowel disease, irritable bowel syndrome, and colon cancer.
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation.
Therapeutic methods of gut microbiota modification in colorectal cancer management - fecal microbiota transplantation, prebiotics, probiotics, and synbiotics.
Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity.
Gut microbiota injury in allogeneic haematopoietic stem cell transplantation.
Colorectal cancer-associated microbiota contributes to oncogenic epigenetic signatures.
Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice.
Faecal microbiota transplantation protects against radiation-induced toxicity.
The intimate relationship between gut microbiota and cancer immunotherapy.
[Intestinal microbiota and allogeneic stem cell transplantation].
Fecal microbiota transplantation: A promising treatment for radiation enteritis?
Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut.
Gut Microbiota and Cancer of the Host: Colliding Interests.
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy.
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
[Advances of fecal microbiota transplantation in improving the prognosis of cancer patients].
Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer.
Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria.
Clostridium difficile colitis: pathogenesis and host defence.
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
Cancer immunotherapy in 2017: The breakthrough of the microbiota.
Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients.
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
[Gut microbiota: What impact on colorectal carcinogenesis and treatment?].
Gavage of Fecal Samples From Patients With Colorectal Cancer Promotes Intestinal Carcinogenesis in Germ-Free and Conventional Mice.
Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders.
[Fecal microbiota transplantation for patients with refractory diarrhea after allogeneic hematopoietic stem cell transplantation].
The gut microbiota in transplant patients.
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.
Gut microbiota contributes towards immunomodulation against cancer: New frontiers in precision cancer therapeutics.
[Fecal microbiota transplantation for acute graft-versus-host disease of the gut].
Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma.
The Bacterial Microbiota of Gastrointestinal Cancers: Role in Cancer Pathogenesis and Therapeutic Perspectives.
Commensal microbiota affects ischemic stroke outcome by regulating intestinal gammadelta T cells.
Gut Microbiota: Its Potential Roles in Pancreatic Cancer.
Potential of fecal microbiota for early-stage detection of colorectal cancer.
Clinical Review on the Utility of Fecal Microbiota Transplantation in Immunocompromised Patients.
Secondary bile acid-induced dysbiosis promotes intestinal carcinogenesis.
[The Relationship between Gut Microbiome, Immune System, and Cancer].
Fecal Microbiota Transplantation: Restoring the Injured Microbiome after Allogeneic Hematopoietic Cell Transplantation.
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
The gut microbiota at the intersection of bile acids and intestinal carcinogenesis: An old story, yet mesmerizing.
Gut microbiota: A new piece in understanding hepatocarcinogenesis.
Fecal microbiota transplantation in patients with cancer undergoing treatment.
Fecal microbiota transplantation in the treatment of intestinal steroid-resistant graft-versus-host disease: two case reports and a review of the literature.
[Role of gut microbiota in carcinogenesis and treatment for colorectal cancer].
Microbiome Anomalies in Allogeneic Hematopoietic Cell Transplantation.
Complex interactions between the microbiome and cancer immune therapy.
Adjunctive fecal microbiota transplantation in supportive oncology: Emerging indications and considerations in immunocompromised patients.
Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.
Association between the gut microbiota and patient responses to cancer immune checkpoint inhibitors.
Gut microbiota from colorectal cancer patients enhances the progression of intestinal adenoma in Apc(min/+) mice.
Faecal microbiota transplantation, a promising way to treat colorectal cancer.
Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.
A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant for Clostridium difficile Infection in Immunocompromised Patients.
Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota.
Berberine regulates fecal metabolites to ameliorate 5-fluorouracil induced intestinal mucositis through modulating gut microbiota.
The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future.
Gut Microbiota Manipulation as a Tool for Colorectal Cancer Management: Recent Advances in Its Use for Therapeutic Purposes.
Gut Microbiota Predict Pulmonary Infiltrates after Allogeneic Hematopoietic Cell Transplantation.
Fecal Microbiota Transplantation for Treatment of Severe Clostridioides difficile Colitis in a Pediatric Patient With Non-Hodgkin Lymphoma.
A Review of the Effects of Natural Compounds, Medicinal Plants, and Mushrooms on the Gut Microbiota in Colitis and Cancer.
YYFZBJS ameliorates colorectal cancer progression in Apc(Min/+) mice by remodeling gut microbiota and inhibiting regulatory T-cell generation.
Microbiota transplantation reveals beneficial impact of berberine on hepatotoxicity by improving gut homeostasis.
Impact of the Microbiota on Bacterial Infections during Cancer Treatment.
Microbiome as a Target for Cancer Therapy.
Applications of gut microbiota in patients with hematopoietic stem-cell transplantation.
Gut microbiota regulate tumor metastasis via circRNA/miRNA networks.
The Intestinal Microbiota Plays as a Protective Regulator Against Radiation Pneumonitis.
Epithelial calcineurin controls microbiota-dependent intestinal tumor development.
Autophagy and Gastrointestinal Diseases.
Gut microbiota and acute graft-versus-host disease.
Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients.
Fecal microbiota transplantation with frozen capsules for a patient with refractory acute gut graft-versus-host disease.
Antibiotic-Induced Shifts in Fecal Microbiota Density and Composition during Hematopoietic Stem Cell Transplantation.
Predictive values of colon microbiota in the treatment response to colorectal cancer.
Microbiota modification in hematology: still at the bench or ready for the bedside?
Microbiota modification in hematology: still at the bench or ready for the bedside?
Gut microbiota modulates adoptive cell therapy via CD8alpha dendritic cells and IL-12.
Not just 'immunity': how the microbiota can reshape our approach to cancer immunotherapy.
Could Fecal Transplantation Become Part of PD-1-Based Immunotherapy, Due to Effects of the Intestinal Microbiome?
The Microbiome and Primary Sclerosing Cholangitis.
Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0.
Inhibition effect of glycyrrhiza polysaccharide (GCP) on tumor growth through regulation of the gut microbiota composition.
Fucosylation Deficiency in Mice Leads to Colitis and Adenocarcinoma.
Microbiota maintain colonic homeostasis by activating TLR2/MyD88/PI3K signaling in IL-10-producing regulatory B cells.
Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study.
Transmission and clearance of potential procarcinogenic bacteria during fecal microbiota transplantation for recurrent Clostridioides difficile.
Diagnosis and treatment of Clostridium difficile (C. diff) colitis: Review of the literature and a perspective in gynecologic oncology.
Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria.
Soy Metabolism by Gut Microbiota from Patients with Precancerous Intestinal Lesions.
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition.